Story perspectives

GLP-1 RAs Slash AMD Risk, Show Promise for RA

10/26/2025

35 7

Summary

Story summary

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may reduce nonexudative age-related macular degeneration risk, with 91,408 patients showing an 83.5% reduction versus other weight-loss drugs.
GLP-1 RAs also show benefits for rheumatoid arthritis, improving disease activity and lowering cardiovascular risks.
However, nearly one-third of patients discontinued due to gastrointestinal issues and insurance challenges.
The findings call for further research on GLP-1 RAs' effects on AMD and RA.

1 of 1

Story summary

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may reduce nonexudative age-related macular degeneration risk, with 91,408 patients showing an 83.5% reduction versus other weight-loss drugs.
GLP-1 RAs also show benefits for rheumatoid arthritis, improving disease activity and lowering cardiovascular risks.
However, nearly one-third of patients discontinued due to gastrointestinal issues and insurance challenges.
The findings call for further research on GLP-1 RAs' effects on AMD and RA.